Last reviewed · How we verify
HRIG
At a glance
| Generic name | HRIG |
|---|---|
| Also known as | Human Rabies Immunoglobulin |
| Sponsor | Crucell Holland BV |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase II Trial of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody (PHASE2)
- Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies (PHASE2)
- SYN023 With Rabies Vaccine in Healthy Pediatric Subjects (PHASE1)
- Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adult and Pediatric Population in Thaïland (PHASE3)
- Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adults in Thaïland (PHASE3)
- Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults (PHASE3)
- Study to Evaluate GR1801's Efficacy and Safety (PHASE3)
- Rabies mAb CBB 1 Combination Vaccine in Healthy People With Antibody Neutralization Activity and Safety Phase Clinical Trials (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |